NASDAQ:ZYME Zymeworks (ZYME) Stock Price, News & Analysis $25.03 -0.72 (-2.80%) Closing price 04:00 PM EasternExtended Trading$25.01 -0.02 (-0.10%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Zymeworks Stock (NASDAQ:ZYME) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Zymeworks alerts:Sign Up Key Stats Today's Range$24.94▼$25.8650-Day Range$23.54▼$31.0552-Week Range$16.00▼$31.34Volume631,861 shsAverage Volume727,229 shsMarket Capitalization$1.78 billionP/E RatioN/ADividend YieldN/APrice Target$40.64Consensus RatingModerate Buy Company Overview Zymeworks Inc. (NASDAQ: ZYME) is a biopharmaceutical company focused on discovering, developing and commercializing engineered antibody-based therapeutics for cancer and other serious diseases. The company’s technologies are designed to create bispecific and multispecific antibodies, as well as antibody-drug conjugates that can target tumor cells and deliver therapeutic payloads. Zymeworks’ leading product is zanidatamab, marketed in the United States as Ziihera. The bispecific antibody targets two separate sites on the HER2 protein and received U.S. Food and Drug Administration accelerated approval in 2024 for previously treated, unresectable, locally advanced or metastatic HER2-positive biliary tract cancer. The company continues to study zanidatamab in additional HER2-expressing cancers and treatment settings. The company’s research is supported by its proprietary Azymetric bispecific antibody and ZymeLink antibody-drug conjugate platforms. Founded in Vancouver, British Columbia, Zymeworks conducts research and development activities in North America and works with pharmaceutical partners to advance and commercialize its therapies in international markets. Its development portfolio has included additional antibody-based candidates for oncology applications.AI Generated. May Contain Errors. Read More Zymeworks Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreZYME MarketRank™: 3.056785621255 of 5 starsZymeworks scored higher than 61% of companies evaluated by MarketBeat, and ranked 437th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingZymeworks has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on no strong buy ratings, 11 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialZymeworks has a consensus price target of $40.64, representing about 60.0% upside from its current price of $25.41.Amount of Analyst CoverageZymeworks has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Zymeworks' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings Growth-15.83% Earnings GrowthEarnings for Zymeworks are expected to decrease by -15.83% in the coming year, from $1.20 to $1.01 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zymeworks is -12.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zymeworks is -12.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZymeworks has a P/B Ratio of 7.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Zymeworks' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.21% of the float of Zymeworks has been sold short.Short Interest Ratio / Days to CoverZymeworks has a short interest ratio ("days to cover") of 5.55.Change versus previous monthShort interest in Zymeworks has recently increased by 7.13%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldZymeworks does not currently pay a dividend.Dividend GrowthZymeworks does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.76 News SentimentZymeworks has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Zymeworks this week, compared to 5 articles on an average week.Search Interest4 people have searched for ZYME on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows5 people have added Zymeworks to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Zymeworks insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $357,557.00 in company stock.Percentage Held by Insiders33.51% of the stock of Zymeworks is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions92.89% of the stock of Zymeworks is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Zymeworks' insider trading history. Receive ZYME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zymeworks and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZYME Stock News HeadlinesZymeworks Sets Q3 2026 Results Date and Ramps Up Investor Conference PresenceOctober 15 at 6:51 AM | tipranks.comZymeworks Announces Third Quarter 2026 Financial Results Date and Upcoming Investor Conference ParticipationOctober 15 at 6:30 AM | quiverquant.comQTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and payment networks that bypass the dollar entirely. Since the Federal Reserve opened in 1913, the dollar has lost most of its purchasing power. Porter Stansberry argues a new monetary order is forming around AI infrastructure, chips and energy, pointing to stocks like Vertiv, GE Vernova and Arista Networks that have surged hundreds of percent in recent years.October 16 at 1:00 AM | Porter & Company (Ad)Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial ResultsOctober 15 at 6:10 AM | financialpost.comFZymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial ResultsOctober 15 at 6:00 AM | globenewswire.comZymeworks (NASDAQ:ZYME) EVP Sells $357,557.20 in StockOctober 12, 2026 | americanbankingnews.comZymeworks (NASDAQ:ZYME) EVP Adam Schayowitz Sells 13,832 Shares of Company StockOctober 10, 2026 | insidertrades.comZymeworks (ZYME) Could Be 39% Undervalued On 2026 Revenue Guidance And CIO HireOctober 9, 2026 | finance.yahoo.comSee More Headlines ZYME Stock Analysis - Frequently Asked Questions How have ZYME shares performed this year? Zymeworks' stock was trading at $26.33 at the beginning of 2026. Since then, ZYME shares have decreased by 3.5% and is now trading at $25.4050. How were Zymeworks' earnings last quarter? Zymeworks Inc. (NASDAQ:ZYME) posted its quarterly earnings data on Friday, August, 7th. The company reported ($0.62) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by $0.06. The company's revenue was down 90.6% on a year-over-year basis. How will Zymeworks' stock buyback program work? Zymeworks' Board of Directors initiated a share repurchase program on Thursday, May 14th 2026, which authorizes the company to repurchase $125,000,000 in outstanding shares, according to EventVestor. This means that the company could repurchase up to 7% of its shares through open market purchases. Shares buyback programs are typically an indication that the company's board believes its stock is undervalued. When did Zymeworks IPO? Zymeworks (ZYME) raised $65 million in an initial public offering (IPO) on Friday, December 16th 2022. The company issued 4,500,000 shares at a price of $13.00-$16.00 per share. Who are Zymeworks' major shareholders? Zymeworks' top institutional investors include Assenagon Asset Management S.A. (2.13%) and State of Alaska Department of Revenue (0.01%). Insiders that own company stock include Ecor1 Capital, Llc, Kenneth Galbraith, Mark Hollywood, Paul Andrew Moore, Jeffrey T L Smith, Adam Schayowitz and Christopher Astle. View institutional ownership trends. How do I buy shares of Zymeworks? Shares of ZYME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Zymeworks own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zymeworks investors own include Advanced Micro Devices (AMD), Palantir Technologies (PLTR), Rocket Lab (RKLB), Intel (INTC), Chevron (CVX), NVIDIA (NVDA) and NuScale Power (SMR). Company Calendar Last Earnings8/07/2026Today10/16/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ZYME's financial health is in the Green zone, according to TradeSmith. ZYME has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ZYME Previous SymbolNASDAQ:ZYME CIK1937653 Webzymeworks.com Phone(302) 274-8744Fax604-737-7077Employees264Year Founded2003Price Target and Rating Average Price Target for Zymeworks$40.64 High Price Target$58.00 Low Price Target$32.00 Potential Upside/Downside+62.3%Consensus RatingModerate Buy Rating Score (0-4)2.77 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($2.02) Trailing P/E RatioN/A Forward P/E Ratio20.86 P/E GrowthN/ANet Income-$81.13 million Net Margins-405.31% Pretax Margin-407.76% Return on Equity-72.30% Return on Assets-37.18% Debt Debt-to-Equity RatioN/A Current Ratio6.32 Quick Ratio6.32 Sales & Book Value Annual Sales$105.96 million Price / Sales16.76 Cash FlowN/A Price / Cash FlowN/A Book Value$3.59 per share Price / Book6.97Miscellaneous Outstanding Shares70,960,000Free Float47,181,000Market Cap$1.78 billion OptionableN/A Beta1.17 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:ZYME) was last updated on 10/16/2026 by MarketBeat.com Staff. From Our Partners$29.97... or free todayBill Poulos's report, The Trading For Income System, normally sells for $29.97. Today, it's free through this ...Profits Run | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredBezos… DOOMED?A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredElon pays this company. Every time.Every Tesla built since 2012 pays this small, overlooked supplier a fee for its technology. So does every Star...Behind the Markets | SponsoredWhy Some AI Stocks Already Surged Over 300 PercentJason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run...Brownstone Research | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredNobody is talking about this…After the Dot-Com Bubble burst in March 2000, the Nasdaq fell 78% over the following decade. But gold staged a...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zymeworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zymeworks With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
